These data indicated that the direct inhibition of CCL4 with CCL4 antibodies could efficiently attenuate circulating CCL4 levels and abolish the increase in circulating inflammatory cytokines, along with atherosclerosis progression. Here, CCL4 is linked to atherosclerosis.